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Abstract
Introduction: A litany of recent evidence supports the morbidity of intra-natal iron-deficiency
anemia and its prodrome, iron deficiency. Oral iron administered during second and third
trimesters does not get to the developing fetus if the mother is iron deficient. This is especially
concerning as the rapidly developing fetal brain is in particular need of iron sufficiency. Intranatal iron deficiency is associated with autism, schizophrenia and abnormal brain structure.
The obstetrical literature reports an unacceptably high incidence of gastrointestinal adverse
events with oral iron. The time iron honored standard in the United States for intravenous iron
replenishment in gravidas is iron sucrose. While safe and effective, four to seven visits are
required to accomplish what newer formulations can achieve with one.
Methods: Ferumoxytol is a superparamagnetic iron oxide linked to polyglucose sorbitol
carboxymethylether-binding elemental iron tightly allowing administration of complete
replacement doses in 15–30 min. Herein, we report the results of 131 consecutive, nonselected, iron-deficient second- and third-trimester pregnant women who received either
510 mg of intravenous (IV) ferumoxytol twice or 1020 mg once.
Results: Hemoglobin and iron parameter increments were highly statistically significant. No
adverse events were reported. We report how a single infusion is safe and effective as the
same dose over two visits, saving an unnecessary visit and IV placement, while reducing cost.
Conclusion: Ferumoxytol represents an efficacious and safe method of administration of IV
iron which improves convenience for patients and practitioners, and is cost saving due to
fewer visits.
Keywords: intravenous iron, iron deficiency, pregnancy, total dose infusion
Received: 22 January 2021; revised manuscript accepted: 27 April 2021.

Plain language summary
One or two infusions of intravenous iron for iron deficiency or iron-deficiency anemia
of pregnancy simplifies care
This study was conducted to highlight the inconvenience of multiple doses of IV iron and
how administering the same dose in one or two infusions simplifies care. We report
how a single infusion is as safe and effective as the same dose over two visits, saving an
unnecessary visit and IV placement, while reducing cost. This study supports a growing
body of evidence, to date, unreported, with ferumoxytol in pregnancy, reporting improved
convenience and decreased costs with higher doses of IV iron in one or two visits.
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Introduction
The magnitude of morbidity of iron-deficiency
anemia (IDA), and its prodrome iron deficiency, is
becoming more and more apparent in pregnancy
with a litany of high-quality publications in the
recent literature. In a prospective study of 2400
iron-deficient women supplemented with oral
iron,1 mothers’ parameters improved; however,
45% of the neonates were iron deficient, based on
cord-blood ferritin concentrations. A more recent,
particularly poignant report of a cohort of 532,232
Swedish individuals2 testing the hypothesis that
‘anemia diagnosed in mothers during pregnancy is
associated with an increased risk of autism spectrum disorders,’ reported anemia at any time during pregnancy was associated with a statistically
significant risk. Among the multifactorial etiologies
of anemia in pregnancy, iron deficiency is the overwhelmingly most common. Supporting the urgency
of addressing iron deficiency and consistent with
the result of the Swedish study, a recent review in
the American Journal of Obstetrics and Gynecology3
noted that the rapidly developing fetal brain is at
particular risk of iron deficiency, which can occur
as a proximate result of maternal iron lack. This
review cogently reported low maternal gestational
iron intake is associated with autism, schizophrenia, and abnormal brain structure in the offspring
with documented deficits which can be measured
with validated tools of recognition memory, slower
speed of processing and poorer bonding, which
persist after postnatal iron repletion. These daunting observations stress the importance of intra-natal
iron sufficiency in deference to postnatal repletion.
It is self-evident to write that treatment of iron
deficiency of pregnancy is iron replacement. The
frontline standard, oral iron, is inexpensive, widely
available and in the non-gravid state, often effective when taken and tolerated. Sadly, this duet is
the exception rather than the rule. A high-quality
meta-analysis of 6831 patients, many of whom
were pregnant, reported greater than 70% of those
to whom oral iron was prescribed reported unacceptable gastrointestinal perturbation,4 and the
obstetrical literature has numerous reports of
unacceptably high incidences of gastrointestinal
side effects.5,6 These data have led to recommendations that intravenous (IV), and not oral iron,
be frontline therapy for gravidas in the second
trimester, with hemoglobin concentrations
<10.5 g/dl and for all anemic women in the third
trimester.7,8 The recently revised United Kingdom

2

guidelines are consistent with these recommendations9 (“IV iron should be considered from the
second trimester onwards for women with confirmed IDA who are intolerant of, or do not
response to, oral iron” (2B). IV iron should be
considered for women who present after 34 weeks’
gestation with confirmed IDA and hemoglobin of
<100 g/dl (1C).
Multiple formulations of IV iron are available for
commercial use in North America, Europe, and
Asia. Iron sucrose, the often standard formulation
for iron repletion in pregnancy, is safe and effective. However, unlike newer formulations with carbohydrate shells which bind elemental iron more
tightly, allowing complete replacement of iron
deficits in 15–30 min, doses of iron sucrose exceeding 200–250 mg are proscribed10 due to an unacceptably high incidence of vasoactive reactions.
One of these newer formulations, ferumoxytol
(Feraheme, AMAG Pharmaceuticals, Waltham,
MA, USA) is a superparamagnetic iron-oxide
compound linked to polyglucose sorbitol carboxymethylether.11 This complex carbohydrate coating
binds elemental iron tightly, allowing administration of large doses in 15–30 min. Ferumoxytol was
approved in the United States in 2009 for use in
iron deficiency associated with chronic kidney disease. The original label allowed a single vial of
510 mg in 17 ml, to be infused very rapidly in as
fast as 17 s (1 ml/s). This approach was associated
with an unacceptably high incidence of infusion
reactions, likely due to complement activation by
labile free iron.12,13 In 2015, the US Food and
Drug Administration (FDA) issued a change in
the label for administering ferumoxytol as a slower
510 mg infusion over 15 min, with a second infusion approximately 1 week later. To obtain a
broader label, the manufacturer performed a double-blind comparison of ferumoxytol with ferric
carboxymaltose (another formulation which allows
a large dose to be administered over a short period
of time) in 1997 patients.14 Two vials (1020 mg) of
ferumoxytol were compared with two vials
(1500 mg) of ferric carboxymaltose administered
according to FDA labeling, with safety as the primary endpoint. A blinded, independent safety
monitoring board assessed all potential reports for
toxicity–hypersensitivity reactions, including anaphylaxis or hypotension. No difference in adverse
events was noted, nor was there a clinically significant difference in change in hemoglobin
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concentration at 5 weeks, despite the higher dose
of ferric carboxymaltose. As a result, in February
of 2018, ferumoxytol was granted a broad label for
use in all causes of IDA after oral iron intolerance,
or for those conditions in which oral iron is ineffective or harmful.
In 2017, we published the first prospective study
of intravenous iron performed in the United
States in 74 oral-iron-intolerant, iron-deficient
second- and third-trimester gravidas.15 A highly
statistically significant increase in hemoglobin
concentration and iron parameters was reported,
as well as a statistically significant increment in
patient-reported outcomes using a Visual Linear
Analog Scale analysis. The formulation and
administration method used was 1000 mg of lowmolecular-weight iron dextran administered over
1 h. No serious adverse events were observed, and
the authors concluded that a total dose infusion
of intravenous iron represented an improved
method of iron repletion in pregnancy, and was
safe, effective, associated with fewer side effects
than oral iron, more convenient, and less expensive than those formulations requiring multiple
infusions. Subsequently, after thousands of infusions of ferumoxytol administered in our practice
as 510 mg in two intravenous infusions on different days, according to the FDA label, the insurance carriers of the bulk of our patient population
were approached. We had previously published
the safety, efficacy and felicitousness of a single
1020 mg infusion of ferumoxytol given in 15 min16
in a 60-patient pilot study, as well as an updated
safety and efficacy analysis of our experience in
184 consecutive, non-selected iron-deficient
patients across a wide spectrum of disorders, who
received 1020 mg of ferumoxytol as a single
30 min infusion.17 Of these 184, 33 were pregnant
and in the second or third trimester. In both
series, no serious adverse events were observed,
with an efficacy defined as ⩾1 g increment in
hemoglobin concentration over a minimum of
4 weeks that approached 100%. Since that publication, we have treated hundreds of pregnant
women with a total dose infusion of 1020 mg ferumoxytol in 30 min without a single serious
adverse event. Herein, we report the results of the
first 131 consecutive, non-selected, iron-deficient
gravidas referred to our practice for treatment of
IDA of pregnancy, who received either a single
1020 mg or two 510 mg infusions of ferumoxytol.
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Methods
The electronic medical records of 131 consecutive, non-selected pregnant women in the second
or third trimester referred to a community hematology practice for the evaluation and treatment
of IDA were reviewed. The start date was chosen
with the administration of the first total dose infusion of 1020 mg ferumoxytol following the initial
insurance approval, by Maryland Blue Cross Blue
Shield CareFirst, for the total dose infusion.
While off label, this method of administration is
standard in our practice and all demographic data
were redacted, such that institutional review
board approval and informed consent was obviated. A secure patient portal website was utilized
to access data. Baseline de-identified demographic information (age, week of gestation at
time of treatment, gravidity, and parity) was
obtained. Baseline laboratory data were obtained
within 4–5 weeks of administration of ferumoxytol, along with the ferumoxytol dosing regimen.
Follow-up data consisted of hemoglobin concentration and iron indices at approximately 4 weeks
(window 3–5 weeks). Where available, pregnancy
outcomes and neonatal statuses were obtained.
Any, and all, adverse events, occurring during or
immediately after administration of IV iron, as
well as any reported in the following week were
collected, including any treatment administered
or pre-medication and resolution of the event.
Consecutive, non-selected pregnant women
referred for treatment of IDA in the second or
third trimester of pregnancy, received either two
infusions of 510 mg of ferumoxytol over 15 min
on separate days, 3–8 days apart (according to
label), or 1020 mg as a single infusion over 30 min
(as permitted by insurance). No pre-medication
was administered, unless there was a history of
multiple drug allergies or asthma (n = 4), in which
case methylprednisolone and ranitidine were
administered intravenously prior to the infusion.
The decision to administer IV iron was made on
the basis of a serum ferritin <30 ng/ml and/or a
percent transferrin saturation (TSAT = serum
iron/total iron-binding capacity) <20% irrespective of hemoglobin concentration (although
hemoglobin results were captured).
Participant demographic and pregnancy characteristics, and baseline and follow-up laboratory
values were described overall and within each
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Table 1. Demographic and pregnancy characteristics.
Total n = 131

510 mg n = 79

1020 mg n = 52

p valuea

Maternal age, years, mean (SD)

29.6 (5.8)

29.8 (5.8)

29.3 (5.9)

0.60

Gravida, mean (SD)

3.1 (1.7)

3.0 (1.6)

3.3 (1.9)

0.32

1

23 (18.4)

14 (18.7)

9 (18.0)

0.91

2

31 (24.8)

20 (26.7)

11 (22.0)

3

22 (17.6)

12 (16.0)

10 (20.0)

4+

49 (39.2)

29 (38.7)

20 (40.0)

Parity, mean (SD)

1.2 (1.0)

1.2 (1.1)

1.1 (0.9)

0.59

0

36 (29.0)

23 (31.1)

13 (26.0)

0.52

1

47 (37.9)

25 (33.8)

22 (44.0)

2+

41 (33.1)

26 (35.1)

15 (30.0)

Gestational age at first treatment,
weeks, mean (SD)

29.4 (5.7)

30.0 (5.3)

28.4 (6.1)

Gravida, n (%)

Parity, n (%)

0.11

ap value from Chi-square test or t test of 510 mg versus 1020 mg.
SD, standard deviation.

study group. Means and standard deviations were
produced for continuous variables, and frequency
counts and percentages were generated for
describing variables that were dichotomous or
polytomous in nature. The balance of characteristics between the 510 mg and the 1020 mg groups
were compared using two-sample t tests for continuous variables and chi-square or Fisher’s exact
tests for categorical variables. Changes in laboratory values from baseline to follow up were calculated, and the mean change in values was
compared using t tests.
Results
A total of 52 subjects received 1020 mg as a single
30 min infusion, and 79 as 510 mg in two 15 min
infusions on different days. Demographic and
pregnancy characteristics of all subjects and by
type of infusion (510 mg or 1020 mg) are found in
Table 1. The mean age for all subjects was
29.6 years with a range of 19–42 years. The mean
gestational age was 29.4 weeks with a range of
14–38 weeks. A total of 18 women were in the

4

second trimester and 107 in the third. The mean
gravidity was 3.1, with a range of 1–10 (Table 1).
The mean time to follow up following the initial
infusion was 13.7 weeks (range 4–29 weeks). The
mean change in hemoglobin from baseline to follow up was 1.9 g/dl (p < 0.0001). A similar benefit
was observed for both TSAT (mean change
17.1%; p < 0.0001) and serum ferritin (mean
change 113.3 ng/ml; p < 0.0001).
Baseline and follow-up lab values of all subjects
and by type of infusion (510 mg or 1020 mg) are
shown in Tables 2 and 3, respectively. The mean
change in hemoglobin from baseline to follow up
was 1.8 g/dl and 2.3 g/dl for the 510 mg and
1020 mg groups, respectively (p = 0.80). The
mean change in TSAT from baseline to follow up
was 19.1% and 14.3% for the 510 mg and
1020 mg groups, respectively (p = 0.30). The
mean change in ferritin from baseline to follow up
was 134.9 ng/ml and 79.2 ng/ml for the 510 mg
and 1020 mg groups, respectively (p = 0.03). The
mean change in mean corpuscular volume from
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Table 2. Baseline hemoglobin and iron parameters.
Total n = 131 mean (SD)

510 mg n = 79 mean (SD)

1020 mg n = 52 mean (SD)

p valuea

Hemoglobin, g/dl

10.0 (0.9)

10.0 (0.9)

9.9 (0.1)

0.76

Ferritin, ng/ml

17.2 (26.3)

18.9 (32.8)

14.6 (10.4)

0.28

TSAT, %

12.1 (7.1)

12.4 (6.7)

11.7 (7.7)

0.58

MCV, fl

81.6 (7.3)

82.3 (7.0)

80.7 (7.7)

0.24

ap value from t test of 510 mg versus 1020 mg.
MCV, mean corpuscular volume; SD, standard deviation; TSAT, transferrin saturation.

Table 3. Follow-up hemoglobin and iron parameters.
Total n = 75, mean (SD)

510 mg, n = 48 mean (SD)

1020 mg, n = 27, mean (SD)

p valuea

Hemoglobin, g/dl

11.9 (1.2)

11.8 (1.4)

12.1 (0.9)

0.36

Ferritin, ng/ml

129.6 (110.1)

151.6 (114.2)

94.9 (95.4)

0.04

TSAT, %

29.2 (18.7)

31.7 (19.5)

25.1 (16.9)

0.16

MCV, fl

84.0 (12.5)

83.0 (14.9)

85.7 (6.5)

0.28

ap value from t test of 510 mg versus 1020 mg.
MCV, mean corpuscular volume; SD, standard deviation; TSAT, transferrin saturation.

baseline to follow up was 1.8 fl and 5.2 fl for the
510 mg and 1020 mg groups, respectively
(p = 0.29).
Among all infusions of 1020 mg or 510 mg, minor
infusion reactions were observed in 19, of which
11 occurred with the 510 mg infusion, and 8 with
the 1020 mg infusion (Table 4). These reactions
consisted of pressure in the chest and/or back,
facial flushing, or nasal congestion. All were selflimited, resolved within minutes, and all but one
(patient refused) received the planned dose.
There were no serious adverse events, episodes of
hypotension or hospitalizations. Prior to resumption of the planned therapy, 16 women received
methylprednisolone and either ranitidine or
famotidine without recurrence of the reaction.
For the 72 in whom post-partum data were available, none reported adverse events at delivery.
Discussion
Recently published evidence reports statistically
significant increments in neurodevelopmental
disorders in children born with iron deficiency
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compared with those sufficient. Failure to insure
intra-natal iron sufficiency is associated with
immediate18 and long-term deficits and with an
increased risk of postnatal iron deficiency despite
oral iron supplementation of the mother.19,20
These data shift the emphasis on iron repletion to
intra-natal iron sufficiency rather than post-natal
repletion. Additionally, iron deficiency is associated with preterm labor, peripartum hemorrhage
and a small but measurable increment in maternal mortality. Oral iron, the current frontline
therapy for iron deficiency of pregnancy is associated with gastrointestinal adverse events in the
majority of women, with resultant poor adherence, informing on a need for IV iron. While iron
sucrose, the time-honored standard for IV iron
repletion in pregnancy is effective and safe, four
to seven visits, each requiring the placement of an
IV access device, are required. Therefore, there is
need to add to the armamentarium of IV iron formulations that are more easily administered. In
this report of 131 iron-deficient pregnant women
with anemia, we report on the safety and efficacy
of IV ferumoxytol, 79 of whom received two
510 mg doses and 52, 1020 mg once. Efficacy was
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Table 4. Adverse reactions for 510 mg and 1020 mg ferumoxytol infusions.

510 mg

1020 mg

Subject

Symptom

1

Flushing and chest pain (infusion stopped) then restarted and
completed; flushing, SOB (infusion stopped and then completed)

2

Abdominal pain, headache, flush, chest tightness

3

Nasal congestion 10 min after ferumoxytol

4

Lightheadedness

5

Chest pressure, SOB, flushing, back pain

6

SOB and chest pressure

7

Flushing, chest pressure; resolved with fluids

8

Chest tightness

9

Nausea and nasal congestion

10

Facial itching

11

Flushing and nausea

1

Lightheadedness

2

Flushing, infusion stopped, restarted at slower rate; completed
without further difficulty

3

Tightness in chest and SOB

4

Fatigue

5

Flushing, nausea after ranitidine and methylprednisolone

6

Facial flushing; subsided when infusion stopped

7

Cough, scratchy throat

8

Cough

Adverse reactions for 510 mg: n = 11; 1020 mg: n = 8.
SOB, shortness of breath.

6

demonstrated by a mean hemoglobin increment
of 1.9 g/dl (1.8 g/dl in the 510 mg given twice, and
2.3 g/dl in the 1020 mg infused once, cohorts,
respectively). No serious adverse events were
observed.

respectively. In a retrospective analysis of 176
consecutive, non-selected patients, 33 of whom
were pregnant in the second and third trimester,
all received 184 infusions of 1020 mg of ferumoxytol. No serious adverse events were observed.17

Consistent with these data, is a prospective study
of 60 oral-iron-intolerant patients who received
1020 mg of ferumoxytol administered in 15 min.16
The primary endpoint was safety and tolerability,
with secondary endpoints, change in hemoglobin
concentration and TSAT. No serious adverse
events were observed. The mean increments at
4 weeks and 8 weeks were 2.1 g/dl and 2.6 g/dl,

The approximate 2 g/dl increase in hemoglobin in
this current series was comparable with the efficacy
previously demonstrated with the 1020 mg administration,16,17 in populations with a diverse etiology
of IDA, as well as what has been reported in the
literature with the FDA-approved regimen of
510 mg given twice.14,21,22 Likely of even greater
interest to practitioners is the safety and tolerability
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of ferumoxytol given during the second or third trimester. Few adverse events, none serious, and all
self-limited, occurred with either administration
paradigm. This experience with the tolerability of
ferumoxytol mirrors what we have noted with the
use of several thousand doses of ferumoxytol in the
authors’ practice, as well as with the several other
IV iron formulations we have employed.
The preponderance of published evidence supports an increased use of IV iron for iron deficiency of pregnancy. In this series of 131, we
demonstrate the safety and efficacy of ferumoxytol in pregnancy. The ability to administer a
full replacement dose of IV iron in 15–30 min,
increases convenience to both practitioners
and patients, decreases cost, and improves
adherence.
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